CHARLES ELDRIDGE: Open Payments
NPI 1871162206 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,040 in 130 payments from 14 companies in 2025. Trend: 2023 $2,200 · 2024 $1,628 · 2025 $2,040
Food & beverage: $2,033Education: $8
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 35 | $447 |
| ABBVIE INC. | 22 | $284 |
| Otsuka America Pharmaceutical, Inc. | 13 | $205 |
| Alkermes, Inc. | 11 | $175 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $163 |
| Neurocrine BioSciences, Inc. | 8 | $161 |
| Janssen Pharmaceuticals, Inc | 6 | $133 |
| Supernus Pharmaceuticals, Inc. | 11 | $122 |
| Vanda Pharmaceuticals Inc. | 1 | $113 |
| Lundbeck LLC | 5 | $80 |
Products named: COBENFY, VRAYLAR, ARISTADA, CAPLYTA, INGREZZA, ABILIFY ASIMTUFII, Qelbree, REXULTI.
Industry payments across MO — which companies pay providers there.
